KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Ratio (2017 - 2026)

Aquestive Therapeutics has reported Equity Ratio over the past 9 years, most recently at 0.21 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 64.62% year-over-year to 0.21; the TTM value through Dec 2025 reached 0.21, up 64.62%, while the annual FY2025 figure was 0.21, 64.62% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.21 at Aquestive Therapeutics, down from 0.03 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.03 in Q3 2025 and troughed at 2.08 in Q3 2022.
  • A 5-year average of 1.09 and a median of 0.88 in 2021 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: crashed 158.98% in 2021 and later skyrocketed 93.92% in 2025.
  • Year by year, Equity Ratio stood at 1.32 in 2021, then tumbled by 56.79% to 2.08 in 2022, then rose by 10.72% to 1.85 in 2023, then soared by 68.02% to 0.59 in 2024, then surged by 64.62% to 0.21 in 2025.
  • Business Quant data shows Equity Ratio for AQST at 0.21 in Q4 2025, 0.03 in Q3 2025, and 0.77 in Q2 2025.